Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

November 13, 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

November 06, 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

September 24, 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

March 12, 2018

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

News Conference News ISET 2018

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

February 13, 2018

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

News Conference News ISET 2018

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

February 08, 2018

Next-Generation Large-Bore Closure Devices Arrive

News Conference News ISET 2018

Next-Generation Large-Bore Closure Devices Arrive

February 05, 2018

Noninvasive Testing of CLI: Many Ways to Draw Up a ‘Roadmap’

News Conference News ISET 2018

Noninvasive Testing of CLI: Many Ways to Draw Up a ‘Roadmap’

February 05, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.